Recce Pharmaceuticals

Headline Sponsor

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to
address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327
as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening
infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally
administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered
mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and
viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic
Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.
Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in
Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is
not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline
seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.

website